《赞德L、卡内塔P、拉斐特R等人。促肾上腺皮质激素治疗进展高危IgA肾病的开放标签试点研究》勘误。2020年；5:58 - 65。
Corrigendum to "Zand L, Canetta P, Lafayette R, et al. An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression." 2020;5:58-65.
出版信息
Kidney Int Rep. 2020 Mar 3;5(3):382. doi: 10.1016/j.ekir.2020.01.024. eCollection 2020 Mar.
Abstract
[This corrects the article DOI: 10.1016/j.ekir.2019.10.007.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.ekir.2019.10.007。]
相似文献
1
Corrigendum to "Zand L, Canetta P, Lafayette R, et al. An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression." 2020;5:58-65.《赞德L、卡内塔P、拉斐特R等人。促肾上腺皮质激素治疗进展高危IgA肾病的开放标签试点研究》勘误。2020年；5:58 - 65。
Kidney Int Rep. 2020 Mar 3;5(3):382. doi: 10.1016/j.ekir.2020.01.024. eCollection 2020 Mar.
2
Corrigendum to Shi M, Yu S, Ouyang Y, et al. Increased lifetime risk of ESRD in familial IgA nephropathy. 2021;6:91-100.对Shi M、Yu S、Ouyang Y等人的勘误：家族性IgA肾病患者终末期肾病终生风险增加。2021年；6：91 - 100。
Kidney Int Rep. 2021 Mar 11;6(5):1484. doi: 10.1016/j.ekir.2021.03.871. eCollection 2021 May.
3
Erratum to Zhang Y, Guo L, Wang Z, Wang J, Er L, Barbour SJ, Trimarchi H, Lv J, Zhang H. "External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort." . 2020;5:1753-1763.张Y、郭L、王Z、王J、鄂L、巴伯SJ、特里马尔基H、吕J、张H的《亚洲-高加索人群中IgA肾病国际风险预测模型的外部验证》勘误。2020年；5:1753 - 1763。
Kidney Int Rep. 2021 Jul 2;6(7):2008-2010. doi: 10.1016/j.ekir.2021.05.023. eCollection 2021 Jul.
4
Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [ 2021; https://doi.org/10.1016/j.ekir.2021.08.020].《依那卡塞在曾接受西那卡塞治疗的继发性甲状旁腺功能亢进患者中的疗效》勘误，[2021年；https://doi.org/10.1016/j.ekir.2021.08.020] 。
Kidney Int Rep. 2021 Nov 5;6(11):2936-2937. doi: 10.1016/j.ekir.2021.09.011. eCollection 2021 Nov.
5
Corrigendum to Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS. 2021;6:313-324.戴维斯 SJ、赵 J、摩根斯特恩 H 等人的《腹膜透析中低血清钾水平与临床结局——国际腹膜透析前瞻性观察性研究（PDOPPS）结果》勘误。2021 年；6：313 - 324。
Kidney Int Rep. 2021 Mar 11;6(5):1485. doi: 10.1016/j.ekir.2021.03.873. eCollection 2021 May.
6
Corrigendum to "Cataldo E, Cinquantini F, Priola AM, et al. Spontaneous renal artery dissection in Ehler-Danlos syndrome." 2019;4:1649-1652.《埃勒斯-当洛综合征中的自发性肾动脉夹层：Cataldo E、Cinquantini F、Priola AM等人的研究》勘误 2019年；4：1649 - 1652
Kidney Int Rep. 2020 Mar 3;5(3):382. doi: 10.1016/j.ekir.2020.01.003. eCollection 2020 Mar.
7
Corrigendum to "The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients" [Kidney Int. Rep. 2020 1416-1421].《中国血液透析患者中 SARS-CoV-2 感染的累积率》[《肾脏国际报告》2020 年第 1416 - 1421 页]勘误
Kidney Int Rep. 2021 Sep;6(9):2525. doi: 10.1016/j.ekir.2021.07.021. Epub 2021 Sep 2.
8
Corrigendum to Inaba M, Une Y, Ikejiri K, et al. "Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial." . 2022;7:177-188.稻叶真人、宇根洋、池尻健等所著《日本接受血液透析的高磷血症患者中替那帕诺的剂量反应——一项2期随机试验》的勘误。2022年；7：177 - 188。
Kidney Int Rep. 2022 Jul 5;7(7):1729. doi: 10.1016/j.ekir.2022.06.008. eCollection 2022 Jul.
9
Corrigendum to "Boudard D, Aureli F, Laurent B, et al. Chronic oral exposure to synthetic amorphous silica (NM-200) results in renal and liver lesions in mice." . 2019;4:1463-1471.《“布达尔D、奥雷利F、洛朗B等人。慢性经口暴露于合成无定形二氧化硅（NM - 200）导致小鼠肾脏和肝脏损伤”》勘误。2019年；4:1463 - 1471。
Kidney Int Rep. 2020 Mar 3;5(3):382. doi: 10.1016/j.ekir.2020.01.002. eCollection 2020 Mar.
10
Corrigendum to "Kimura T, Snijder R, Nozaki K. Diagnosis patterns of CKD and anemia in the Japanese population." . 2020;5:694-705.《木村T、斯奈德R、野崎K。日本人群中慢性肾脏病和贫血的诊断模式》勘误。2020年；5:694 - 705。
Kidney Int Rep. 2020 Sep 3;5(9):1614. doi: 10.1016/j.ekir.2020.08.006. eCollection 2020 Sep.
Zotero 插件